Gamma-aminobutyric acid release (GABA release)

Gamma-aminobutyric acid (GABA) release is the primary physiological mechanism for inhibitory neurotransmission in the mammalian central nervous system. It occurs when GABA-containing synaptic vesicles undergo calcium-dependent exocytosis into the synaptic cleft, typically in response to an action potential reaching the presynaptic terminal (Source: StatPearls, 'Physiology, GABA'). Once released, GABA binds to ionotropic GABA-A receptors or metabotropic GABA-B receptors, leading to neuronal hyperpolarization and reduced excitability (Source: Wikipedia, 'GABAergic'). This process is critical for maintaining the excitatory-inhibitory balance; its dysregulation is a hallmark of neurological conditions such as epilepsy, where deficient GABAergic tone leads to seizures, and psychiatric disorders like anxiety (Source: PubMed, PMID: 24719448). Therapeutic intervention focuses on enhancing GABA availability or release through reuptake inhibition (e.g., Tiagabine) or metabolic preservation (e.g., Vigabatrin), while drugs like Gabapentinoids modulate the calcium channels that trigger the release event itself (Source: NIH, PubChem 'Tiagabine'). Because this target is a biological process rather than a specific protein, it is often categorized pharmacologically by the specific transporters or enzymes that regulate the synaptic concentration of GABA.

Other names

GABAergic neurotransmissionGABAergic signalingPresynaptic GABA exocytosisInhibitory neurotransmitter release

Modulation of GABA release is achieved through several mechanisms: Tiagabine inhibits the GABA transporter GAT-1 to prevent reuptake; Vigabatrin inhibits GABA transaminase (GABA-T) to increase the available pool for release; Gabapentin and Pregabalin bind to the alpha-2-delta subunit of voltage-gated calcium channels to modulate calcium-dependent exocytosis.